Syndax Pharmaceuticals Inc Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug Calliditas Therapeutics AB (

Related Stocks: SNDX ,

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) gapped up prior to trading on Tuesday . The stock had previously closed at $16.53, but opened at $17.85. Syndax Pharmaceuticals shares last traded at $17.84, with a volume of 5,347 shares trading hands. A number of analysts recently issued reports on the company. Zacks Investment Research lowered Syndax Pharmaceuticals from […]

Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed-lineage leukemia rearranged (MLLr) relapsed/refractory acute leukemias. The data were featured at the American Society of Hematology (ASH) Annual Meeting. Across evaluable patients with mNPM1 (n=13) or MLLr (n=38) who received at least one dose of SNDX-5613, the overall response rate (ORR) was 55%, with a complete Full story available on Benzinga.com

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed

Brokerages expect Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to announce earnings per share (EPS) of ($0.68) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Syndax Pharmaceuticals earnings, with estimates ranging from ($0.74) to ($0.62). Syndax Pharmaceuticals posted earnings of ($0.44) per share in the same quarter last year, which indicates []

WALTHAM, Mass., Dec. 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from its Phase 1/2 trial of

WALTHAM, Mass., Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license

Equities research analysts expect Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to post earnings of ($0.68) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Syndax Pharmaceuticals earnings, with estimates ranging from ($0.74) to ($0.62). Syndax Pharmaceuticals reported earnings per share of ($0.44) in the same quarter last year, which []

Credit Suisse AG reduced its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 7.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,945 shares of the companys stock after selling 1,948 shares during the period. Credit Suisse AGs [] The post Credit Suisse AG Sells 1,948 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) appeared first on ETF Daily News .

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -1.46% to the previous days close as strong demand from buyers drove the stock to $16.83. Actively observing the price movement in the last trading, the stock closed the session at $17.08, falling within a range of $16.60 Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Stock Seems Like A Good Option Read More »

Charles Schwab Investment Management Inc. increased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 16.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 269,631 shares of the companys stock after purchasing an additional 38,698 shares during the period. Charles Schwab Investment Management Inc.s []

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Equities research analysts at B. Riley boosted their FY2021 earnings estimates for Syndax Pharmaceuticals in a note issued to investors on Wednesday, November 17th. B. Riley analyst J. Walsh now anticipates that the company will post earnings of ($2.11) per share for the year, up from their prior forecast of []

Syndax Pharmaceuticals (NASDAQ:SNDX) released its quarterly earnings data on Monday. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.24, MarketWatch Earnings reports. Syndax Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 6,031.18%. During the same quarter in the previous year, the []